Allogene Therapeutics Inc... (ALLO)
Allogene Therapeutics Statistics
Share Statistics
Allogene Therapeutics has 209.67M shares outstanding. The number of shares has increased by 24% in one year.
| Shares Outstanding | 209.67M |
| Shares Change (YoY) | 24% |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | 78.58% |
| Shares Floating | 134.74M |
| Failed to Deliver (FTD) Shares | 3.3K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 32.35M, so 15.43% of the outstanding shares have been sold short.
| Short Interest | 32.35M |
| Short % of Shares Out | 15.43% |
| Short % of Float | 22.75% |
| Short Ratio (days to cover) | 10.45 |
Valuation Ratios
The PE ratio is -1.54 and the forward PE ratio is -1.39. Allogene Therapeutics's PEG ratio is 0.17.
| PE Ratio | -1.54 |
| Forward PE | -1.39 |
| PS Ratio | 5302.64 |
| Forward PS | 1.7 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -2.11 |
| PEG Ratio | 0.17 |
Enterprise Valuation
Allogene Therapeutics Inc. has an Enterprise Value (EV) of 515.72M.
| EV / Earnings | -1.58 |
| EV / Sales | 5428.6 |
| EV / EBITDA | -1.72 |
| EV / EBIT | -1.57 |
| EV / FCF | -2.16 |
Financial Position
The company has a current ratio of 12.38, with a Debt / Equity ratio of 0.19.
| Current Ratio | 12.38 |
| Quick Ratio | 12.38 |
| Debt / Equity | 0.19 |
| Total Debt / Capitalization | 15.66 |
| Cash Flow / Debt | -2.5 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.64% and return on capital (ROIC) is -53.96%.
| Return on Equity (ROE) | -0.64% |
| Return on Assets (ROA) | -0.51% |
| Return on Capital (ROIC) | -53.96% |
| Revenue Per Employee | $409.48 |
| Profits Per Employee | $-1,410,625 |
| Employee Count | 232 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -60.53% in the last 52 weeks. The beta is 0.83, so Allogene Therapeutics's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | -60.53% |
| 50-Day Moving Average | 1.96 |
| 200-Day Moving Average | 2.44 |
| Relative Strength Index (RSI) | 49.49 |
| Average Volume (20 Days) | 5.15M |
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 95K and earned -327.26M in profits. Earnings per share was -2.09.
| Revenue | 95K |
| Gross Profit | -242.82M |
| Operating Income | -327.74M |
| Net Income | -327.26M |
| EBITDA | -300.29M |
| EBIT | -327.74M |
| Earnings Per Share (EPS) | -2.09 |
Balance Sheet
The company has 83.16M in cash and 95.12M in debt, giving a net cash position of -11.97M.
| Cash & Cash Equivalents | 83.16M |
| Total Debt | 95.12M |
| Net Cash | -11.97M |
| Retained Earnings | -1.56B |
| Total Assets | 589.12M |
| Working Capital | 271.84M |
Cash Flow
In the last 12 months, operating cash flow was -237.73M and capital expenditures -1.52M, giving a free cash flow of -239.25M.
| Operating Cash Flow | -237.73M |
| Capital Expenditures | -1.52M |
| Free Cash Flow | -239.25M |
| FCF Per Share | -1.52 |
Margins
Gross margin is -255.6K%, with operating and profit margins of -344.99K% and -344.49K%.
| Gross Margin | -255.6K% |
| Operating Margin | -344.99K% |
| Pretax Margin | -344.49K% |
| Profit Margin | -344.49K% |
| EBITDA Margin | -316.1K% |
| EBIT Margin | -344.99K% |
| FCF Margin | -251.84K% |
Dividends & Yields
ALLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -107.18% |
| FCF Yield | -58.67% |
Analyst Forecast
The average price target for ALLO is $9.5, which is 387.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 387.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -3.12 |
| Piotroski F-Score | 2 |